Indrayathi, Putu A.
Indonesian Journal of Clinical Pharmacy

Published : 4 Documents
Articles

Found 4 Documents
Search

Perbedaan Fungsi Ginjal, Hati dan Darah pada Pasien Kanker Serviks dengan Kemoterapi Bleomisin, Oncovin®, Mitomisin dan Karboplatin (Studi Kasus di RSUP Sanglah Denpasar Tahun 2015) Noviyani, Rini; Budiana, I Nyoman G.; Indrayathi, Putu A.; Niruri, Rasmaya; Tunas, I Ketut
Indonesian Journal of Clinical Pharmacy Vol 5, No 4 (2016)
Publisher : Indonesian Journal of Clinical Pharmacy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (552.043 KB) | DOI: 10.15416/ijcp.2016.5.4.269

Abstract

  Regimen Bleomisin Oncovin® Mitomisin-Karboplatin (BOM-Karboplatin) sebagai kemoterapi tidak terlepas dari efek samping yang ditimbulkan yaitu toksisitas pada organ tubuh diantaranya adalah ginjal, hati, dan darah, dimana terjadinya toksikitas pada organ ginjal dapat diindikatorkan dengan parameter Serum Kreatinin dan Blood Urea Nitrogen (BUN). Terjadinya toksisitas pada organ hati dapat diukur dengan parameter SGOT dan SGPT serta toksisitas pada fungsi darah diindikatorkan dengan nilai hemoglobin, trombosit, leukosit. Belum terdapat data mengenai efek toksik dari kemoterapi BOM-Karboplatin pada pasien kanker serviks sel skuamosa stadium IIB–IIIB di RSUP Sanglah Denpasar, sehingga penelitian ini dilakukan melalui pemantauan terhadap fungsi ginjal, hati dan darah. Penelitian ini merupakan studi kasus observasional terhadap sembilan pasien yang diikuti selama tiga seri kemoterapi dari bulan Februari hingga Agustus 2015. Data serum kreatinin, BUN, SGOT, SGPT, hemoglobin, trombosit, dan leukosit yang diperoleh dianalisis menggunakan uji t berpasangan untuk data yang terdistribusi normal dan uji Wilcoxon untuk data yang tidak terdistribusi normal dengan tingkat kepercayaan 95% dan dikatakan berbeda bermakna bila p<0,05. Hasil studi kasus ini menunjukkan nilai serum kreatinin (p=0,530), BUN (p=0,553), SGOT (p=0,162), SGPT (p=0,054), Hemoglobin (p=0,034), Trombosit (p=0,028), dan Leukosit (p=0,011), sehingga dapat disimpulkan bahwa terdapat penurunan fungsi darah yang signifikan ditandai dengan adanya penurunan signifikan pada parameter hemoglobin, trombosit dan leukosit sebelum kemoterapi I dan sesudah kemoterapi III BOM-Karboplatin, sehingga diperlukan monitoring ketat terhadap fungsi darah pasien yang menerima kemoterapi BOM-Karboplatin di RSUP Sanglah Denpasar.Kata kunci: BOM-Karboplatin, fungsi darah, kanker serviks, kemoterapi, RSUP Sanglah, toksisitasThe Difference of Kidney, Heart and Blood Function on Cervical Cancer Patients with Chemotherapy, Bleomycin, Oncovin®, Mitomycin and Carboplatin (Case Study in Sanglah General Hospital, Denpasar in 2015) Oncovin® bleomycin mitomycin-carboplatin (BOM-carboplatin) regimen as chemotherapy is inseparable from the side effects it can caused which is toxicity to organs including the kidneys, liver, and blood where the toxicity in the kidneys can be indicated by the parameter of Serum Creatinine and Blood Urea Nitrogen (BUN), the occurrence of toxicity in the liver can be measured by the parameters of SGOT and SGPT, and toxicity to blood function can be indicated by the value of hemoglobin, platelets, leukocytes. The absence of data on the toxic effects of chemotherapy BOM-carboplatin in patients with squamous cell cervical cancer stage IIB–IIIB in Sanglah General Hospital in Denpasar, had made this research conducted through monitoring of kidney, liver and blood function. This study is an observational case study of nine patients who were followed for three rounds of chemotherapy from February to August 2015. Data of creatinine serum, BUN, SGOT, SGPT, hemoglobin, platelets, and leukocytes were analyzed using paired t-test for the data that were normally distributed and Wilcoxon test for the data that were not normally distributed with a confidence level of 95% and was said to be significantly different when p<0.05. The results of this case study demonstrated the value of serum creatinine (p=0.530), BUN (p=0.553), SGOT (p=0.162), SGPT (p=0.054), hemoglobin (p=0.034), platelets (p=0.028), and leukocytes (p=0.011) so it could be concluded that there was a significant decrease of blood function which could be characterized by a significant decrease in the parameters of hemoglobin, platelets and leucocytes before chemotherapy I and after chemotherapy III BOM-carboplatin, so it required strict monitoring of the blood function of the patients who received chemotherapy BOM-carboplatin in Sanglah General Hospital in Denpasar.Keywords: BOM-carboplatin, blood function, cervical cancer, chemotherapy, Sanglah General Hospital, toxicity
Penilaian Kualitas Hidup Pasien Kanker Serviks dengan Kemoterapi Paklitaksel–Karboplatin di RSUP Sanglah Tunas, I Ketut; Yowani, Sagung C.; Indrayathi, Putu A.; Noviyani, Rini; Budiana, I Nyoman G.
Indonesian Journal of Clinical Pharmacy Vol 5, No 1 (2016)
Publisher : Indonesian Journal of Clinical Pharmacy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (310.193 KB) | DOI: 10.15416/ijcp.2016.5.1.35

Abstract

Pemberian kemoterapi pada pasien kanker serviks stadium IIB-IIIB selain menimbulkan efek terapi juga menimbulkan efek samping berupa penurunan kualitas hidup. Penelitian ini dilakukan pada Februari–Juni 2014 di Bagian Obstetri dan Gineklogi RSUP Sanglah Denpasar secara observasional dengan metode case study prospective. Pengumpulan data dilakukan menggunakan kuesioner EORTC QLQ C30 yang dikombinasikan dengan wawancara sebelum dan setelah kemoterapi paklitaksel-karboplatin sebanyak 3 seri pada pasien kanker serviks sel skuamosa stadium IIB-IIIB. Penelitian kualitas hidup dilakukan secara umum dan pada 15 domain yang memengaruhi kualitas hidup. Terdapat 12 pasien yang memenuhi kriteria inklusi. Pemberian kemoterapi regimen paklitaksel-karboplatin dapat meningkatkan kualitas hidup dengan penurunan nilai mean dari 48,083±5,451 menjadi 44,083±3,872. Terdapat perbedaan bermakna pada nilai kualitas hidup pasien sebelum dan setelah kemoterapi paklitaksel-karboplatin (nilai p=0,038). Terdapat penurunan kualitas hidup pada domain mual muntah, penurunan nafsu makan, fatigue, dan fungsi sosial. Domain dengan peningkatan kualitas hidup yaitu nyeri, fungsi fisik, fungsi emosional, sulit tidur, dan kesulitan keuangan. Pemberian kemoterapi paklitaksel-karboplatin pada 12 pasien dapat meningkatkan kualitas hidup pasien kanker serviks.Kata kunci: Domain kualitas hidup, kanker serviks, kualitas hidup, paklitaksel-karboplatinThe Assessment Quality of Life For Patients with Cervical Cancer Using Chemotherapy Paclitaxel-Carboplatin in Sanglah Chemotherapy administration to patients with cervical cancer stage IIB-IIIB not only causing a therapeutic effect but also decrease in quality of life. This study was conducted in February–June 2014 in the Department of Obstetrics and Gynecology Sanglah Hospital with observational prospective case study method. Data were collected using the EORTC QLQ C30 questionnaire combined with interview before and after chemotherapy paclitaxel-carboplatin as much as 3 series in patients with squamous cell cervical cancer stage IIB-IIIB. Assesment was done in general quality of life and 15 domains that affect the quality of life. There were 12 patients who met the inclusion criteria. Administration chemotherapy with paclitaxel-carboplatin can improve the quality of life shown by decrease mean value from 48.083±5.451 to 44.083±3.872. There were significant differences in the value of the quality of life before and after being given chemotherapy paclitaxel-carboplatin (p-value 0.038). There were decrease in the quality of life of the domain nausea, vomiting, decreased appetite, fatigue, and social functions. Domains that have increased the quality of life is pain, physical functioning, emotional functioning, sleeplessness, and financial difficulties. Administration of chemotherapy paclitaxel-carboplatin can improve the quality of life of patients with cervical cancer.Key words: Domain quality of life, cervical cancer, paclitaxel-carboplatin, quality of life
Perbedaan Fungsi Ginjal, Hati dan Darah pada Pasien Kanker Serviks dengan Kemoterapi Bleomisin, Oncovin®, Mitomisin dan Karboplatin (Studi Kasus di RSUP Sanglah Denpasar Tahun 2015) Noviyani, Rini; Budiana, I Nyoman G.; Indrayathi, Putu A.; Niruri, Rasmaya; Tunas, I Ketut
Indonesian Journal of Clinical Pharmacy Vol 5, No 4 (2016)
Publisher : Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (299.142 KB) | DOI: 10.15416/ijcp.2016.5.4.269

Abstract

  Regimen Bleomisin Oncovin® Mitomisin-Karboplatin (BOM-Karboplatin) sebagai kemoterapi tidak terlepas dari efek samping yang ditimbulkan yaitu toksisitas pada organ tubuh diantaranya adalah ginjal, hati, dan darah, dimana terjadinya toksikitas pada organ ginjal dapat diindikatorkan dengan parameter Serum Kreatinin dan Blood Urea Nitrogen (BUN). Terjadinya toksisitas pada organ hati dapat diukur dengan parameter SGOT dan SGPT serta toksisitas pada fungsi darah diindikatorkan dengan nilai hemoglobin, trombosit, leukosit. Belum terdapat data mengenai efek toksik dari kemoterapi BOM-Karboplatin pada pasien kanker serviks sel skuamosa stadium IIB–IIIB di RSUP Sanglah Denpasar, sehingga penelitian ini dilakukan melalui pemantauan terhadap fungsi ginjal, hati dan darah. Penelitian ini merupakan studi kasus observasional terhadap sembilan pasien yang diikuti selama tiga seri kemoterapi dari bulan Februari hingga Agustus 2015. Data serum kreatinin, BUN, SGOT, SGPT, hemoglobin, trombosit, dan leukosit yang diperoleh dianalisis menggunakan uji t berpasangan untuk data yang terdistribusi normal dan uji Wilcoxon untuk data yang tidak terdistribusi normal dengan tingkat kepercayaan 95% dan dikatakan berbeda bermakna bila p<0,05. Hasil studi kasus ini menunjukkan nilai serum kreatinin (p=0,530), BUN (p=0,553), SGOT (p=0,162), SGPT (p=0,054), Hemoglobin (p=0,034), Trombosit (p=0,028), dan Leukosit (p=0,011), sehingga dapat disimpulkan bahwa terdapat penurunan fungsi darah yang signifikan ditandai dengan adanya penurunan signifikan pada parameter hemoglobin, trombosit dan leukosit sebelum kemoterapi I dan sesudah kemoterapi III BOM-Karboplatin, sehingga diperlukan monitoring ketat terhadap fungsi darah pasien yang menerima kemoterapi BOM-Karboplatin di RSUP Sanglah Denpasar.Kata kunci: BOM-Karboplatin, fungsi darah, kanker serviks, kemoterapi, RSUP Sanglah, toksisitasThe Difference of Kidney, Heart and Blood Function on Cervical Cancer Patients with Chemotherapy, Bleomycin, Oncovin®, Mitomycin and Carboplatin (Case Study in Sanglah General Hospital, Denpasar in 2015) Oncovin® bleomycin mitomycin-carboplatin (BOM-carboplatin) regimen as chemotherapy is inseparable from the side effects it can caused which is toxicity to organs including the kidneys, liver, and blood where the toxicity in the kidneys can be indicated by the parameter of Serum Creatinine and Blood Urea Nitrogen (BUN), the occurrence of toxicity in the liver can be measured by the parameters of SGOT and SGPT, and toxicity to blood function can be indicated by the value of hemoglobin, platelets, leukocytes. The absence of data on the toxic effects of chemotherapy BOM-carboplatin in patients with squamous cell cervical cancer stage IIB–IIIB in Sanglah General Hospital in Denpasar, had made this research conducted through monitoring of kidney, liver and blood function. This study is an observational case study of nine patients who were followed for three rounds of chemotherapy from February to August 2015. Data of creatinine serum, BUN, SGOT, SGPT, hemoglobin, platelets, and leukocytes were analyzed using paired t-test for the data that were normally distributed and Wilcoxon test for the data that were not normally distributed with a confidence level of 95% and was said to be significantly different when p<0.05. The results of this case study demonstrated the value of serum creatinine (p=0.530), BUN (p=0.553), SGOT (p=0.162), SGPT (p=0.054), hemoglobin (p=0.034), platelets (p=0.028), and leukocytes (p=0.011) so it could be concluded that there was a significant decrease of blood function which could be characterized by a significant decrease in the parameters of hemoglobin, platelets and leucocytes before chemotherapy I and after chemotherapy III BOM-carboplatin, so it required strict monitoring of the blood function of the patients who received chemotherapy BOM-carboplatin in Sanglah General Hospital in Denpasar.Keywords: BOM-carboplatin, blood function, cervical cancer, chemotherapy, Sanglah General Hospital, toxicity
Penilaian Kualitas Hidup Pasien Kanker Serviks dengan Kemoterapi Paklitaksel–Karboplatin di RSUP Sanglah Tunas, I Ketut; Yowani, Sagung C.; Indrayathi, Putu A.; Noviyani, Rini; Budiana, I Nyoman G.
Indonesian Journal of Clinical Pharmacy Vol 5, No 1 (2016)
Publisher : Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (291.444 KB) | DOI: 10.15416/ijcp.2016.5.1.35

Abstract

Pemberian kemoterapi pada pasien kanker serviks stadium IIB-IIIB selain menimbulkan efek terapi juga menimbulkan efek samping berupa penurunan kualitas hidup. Penelitian ini dilakukan pada Februari–Juni 2014 di Bagian Obstetri dan Gineklogi RSUP Sanglah Denpasar secara observasional dengan metode case study prospective. Pengumpulan data dilakukan menggunakan kuesioner EORTC QLQ C30 yang dikombinasikan dengan wawancara sebelum dan setelah kemoterapi paklitaksel-karboplatin sebanyak 3 seri pada pasien kanker serviks sel skuamosa stadium IIB-IIIB. Penelitian kualitas hidup dilakukan secara umum dan pada 15 domain yang memengaruhi kualitas hidup. Terdapat 12 pasien yang memenuhi kriteria inklusi. Pemberian kemoterapi regimen paklitaksel-karboplatin dapat meningkatkan kualitas hidup dengan penurunan nilai mean dari 48,083±5,451 menjadi 44,083±3,872. Terdapat perbedaan bermakna pada nilai kualitas hidup pasien sebelum dan setelah kemoterapi paklitaksel-karboplatin (nilai p=0,038). Terdapat penurunan kualitas hidup pada domain mual muntah, penurunan nafsu makan, fatigue, dan fungsi sosial. Domain dengan peningkatan kualitas hidup yaitu nyeri, fungsi fisik, fungsi emosional, sulit tidur, dan kesulitan keuangan. Pemberian kemoterapi paklitaksel-karboplatin pada 12 pasien dapat meningkatkan kualitas hidup pasien kanker serviks.Kata kunci: Domain kualitas hidup, kanker serviks, kualitas hidup, paklitaksel-karboplatinThe Assessment Quality of Life For Patients with Cervical Cancer Using Chemotherapy Paclitaxel-Carboplatin in Sanglah Chemotherapy administration to patients with cervical cancer stage IIB-IIIB not only causing a therapeutic effect but also decrease in quality of life. This study was conducted in February–June 2014 in the Department of Obstetrics and Gynecology Sanglah Hospital with observational prospective case study method. Data were collected using the EORTC QLQ C30 questionnaire combined with interview before and after chemotherapy paclitaxel-carboplatin as much as 3 series in patients with squamous cell cervical cancer stage IIB-IIIB. Assesment was done in general quality of life and 15 domains that affect the quality of life. There were 12 patients who met the inclusion criteria. Administration chemotherapy with paclitaxel-carboplatin can improve the quality of life shown by decrease mean value from 48.083±5.451 to 44.083±3.872. There were significant differences in the value of the quality of life before and after being given chemotherapy paclitaxel-carboplatin (p-value 0.038). There were decrease in the quality of life of the domain nausea, vomiting, decreased appetite, fatigue, and social functions. Domains that have increased the quality of life is pain, physical functioning, emotional functioning, sleeplessness, and financial difficulties. Administration of chemotherapy paclitaxel-carboplatin can improve the quality of life of patients with cervical cancer.Key words: Domain quality of life, cervical cancer, paclitaxel-carboplatin, quality of life